An increasing need exists to understand the benefits of a test drug compared with standard of care (SoC) earlier in development. Even if a drug is superior to placebo, it may not be worthwhile to continue development unless it has advantages over SoC. However, eficacy and safety comparisons versus SoC in early phase studies can be challenging. Analytic studies were conducted to illustrate that in common scenarios simply randomizing a few patients to SoC will frequently yield misleading results. It may take samples sizes at least fivefdd greater to achieve reliable comparisons of a test drug with SoC than when comparing versus placebo. Therefore, it is important that the rate of false positive and false negative results be quantitatively evaluated before determining the sample size and the criteria upon which the test drug and SoC will be compared. Because test drugs often have no benefit, comparing a test drug with SoC may unnecessarily use resources that could be devoted to investigating other drugs. Moreover, it can be difficult to construct valid comparisons of a test drug versus SoC without expetience with the test drug regarding appropriate dosing, patient population, and so on. An example with actual clinical trial data is used to illustrate how the trade-off between the need and the difficulties in comparing a test drug with SoC in phase 2 can be mitigated using a literature database of placebo-contrded studies to construct a historical comparison.
tionally included exploring use for the targeted indication (establishing proof of concept, PoC) Dr. Craig H. Mallinckrodt. Indidnapolis. IN 46285 and estimating dosage for subsequent studies (dose-response) (1,2). One of the changes in recent years in the health care industry is that key stakeholders are demanding evidence not only that drugs are safe and effective, but that they are safer or more effective than alternatives. Therefore, greater need exists to understand the risks and benefits of a test drug compared with a standard of care (SoC). Ideally, this information would be available early in development. For example, even if a test drug were superior to placebo in a PoC study, it might not be worthwhile to continue developing the drug unless it also provides benefit beyond a currently available cheaper, generic therapy.
However, efficacy comparisons versus SoC in a PoC study can be challenging (3,4). For example, reliably establishing a difference be- (email: cmallinc@lilly.com). tween a test drug and SoC most likely will require an appreciably larger sample size to achieve a given level of power than when comparing the test drug with placebo because the SoC is superior to placebo.
The larger sample size required to compare a test drug with SoC has important implications for PoC studies. Given that many drugs tested in PoC studies will have no benefit, that is, they are not better than placebo, does it make sense ethically or financially to do a big trial to compare the test drug with SoC when a small study would show the test drug was not different from placebo? Alternatively, does it make sense to do a smaller study to compare with placebo when SoC is the benchmark that really matters?
It may be tempting to believe that having some data is better than no data: that, all else being equal, including even a few patients in an active comparator arm in a PoC trial is useful for benchmarking the test drug versus the SoC. But that may not necessarily be the case because an unreliable comparison can be a mis-leading comparison, which may not be better than no comparison. And all else is not equal because including an active comparator adds cost, time, and potential logistic or methodological difficulties to the study.
These are questions routinely faced in drug development today. The purpose of this article is to illustrate a framework for addressing these questions. The intent is not to provide specific recommendations for specific scenarios. Rather, the focus is on establishing a framework that provides the basis for addressing the questions.
METHODS

ANALYTIC !3TUDY
A useful way to approach the issues of whether or not direct comparisons with SoC should be part of a PoC study is to consider how reliable the comparison with SoC must be for it to be useful. Specifically, how many patients should be included in the test drug and SoC arms of the trial to have an acceptable rate of false positive and false negative findings?
This question is considered through use of an analytic study. Parameters were input to establish standard normal distributions describing the probabilities of observed differences between a test drug and SoC under varying levels of true differences between the test drug and SoC. The resulting cumulative distribution functions (CDF) were used to compute the probabilities that the test drug would meet various criteria associated with being superior to the SoC. Probabilities were computed using the CDF function in SAS 9.1 (code available upon request).
Several criteria for superiority were considered because definitive hypothesis tests for superiority of the test drug versus SoC likely lead to prohibitively large sample sizes for a PoC study. Thus, in addition to the probability of a significant result on a superiority test, the probabilities of estabhshing noninferiority of the test drug were also considered along with the probability the advantage of the test drug would fall within a certain range, and the probability of properly ranking the test drug and SoC were also considered.
Several scenarios were considered. The first scenario was patterned after schizophrenia clinical trials. A recent meta-analysis reported an effect size of approximately 0.6 for atypical antipsychotics (5). In scenario l A , the test drug was hoped to be superior to SoC by a margin of 0.20 effect size. This effect size would represent a relative gain over SoC of 33% (0.2/0.6). The true effect size for the test drug versus placebo was 0.80, and the effect size for the SoC versus placebo was 0.60, with the effect size for test drug versus SoC equal to the hoped-for advantage of 0.20. With an effect size of 0.8, a sample size of 40 per arm could be adequate for comparisons with placebo as this contrast would have approximately 90% power. Therefore, the sample sizes considered for scenario 1 included N = 40, 100, or 200 per arm. In scenario l B , the same general parameters were considered except that the test drug was not different from SoC as the test drug and SoC each had an effect size versus placebo of 0.60.
Scenario 2 was similar to scenario 1 except effect sizes were smaller, mimicking scenarios in major depressive disorder (MDD) where a recent meta-analysis showed the average effect size over placebo to be 0.31 (6). In scenario 2A, the effect size for the test drug versus placebo was 0.40, and the effect size for the SoC versus placebo was 0.30, with the effect size for test drug versus SoC equal to the hoped-for advantage of 0.10. With an effect size of 0.4, a sample size of 100 per arm could be adequate for comparisons with placebo as this contrast would have approximately 80% power. Therefore, the sample sizes considered for scenario 2 included N = 100, 200, or 500 per arm. In scenario 2B. the same general parameters were considered except the test drug was not different from SoC, as the test drug and SoC each had an effect size versus placebo of 0.30.
Superiority of the test drug was based on hypothesis testing using alpha = .05. For the noninferiority test, noninferiority was declared if the lower bound of the 95% confidence interval was greater than an effect size of -0.2 in scenario 1 and -0.1 in scenario 2. These lower bounds were chosen because they preserve two
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thirds of the advantage of the active drug over placebo. The rank test was based simply on whether or not the test drug was numerically superior to SoC. (Test drug had greater mean change than SoC by any amount.) The range test was used to assess whether or not the estimated superiority of the test drug fell within the range of one half of the hoped-for advantage to twice the hoped-for advantage. This measure is an intuitive assessment of whether or not the study yielded a reliable result. For scenario 1 the range was 0.1-0.4 (1/2 0.2 to 2 * 0.2) and for scenario 2 the range was 0.05-0.2 (1/2 * 0.1 to 2 0.1).
REAL DATA EXAMPLE OF USING A LITERATURE DATABASE TO BENCHMARK
VERSUS SOC
Selective serotonin reuptake inhibitors (SSRls) have been tested extensively in the treatment of MDD. So the effect size is essentially known. From the historical data, the average effect size of MDD treatments = 0.31 (6). Prior to approval of duloxetine for major depressive disorder, 11 clinical trials were conducted that included 15 treatment arms of duloxetine tested versus placebo. In seven of these studies, which included 11 duloxetine treatment arms, a positive control (SSRI) was also included. Among these seven SSRl arms, five had equal randomization to duloxetine and two had half as many patients as duloxetine. These studies have been published individually (7-14) and in summaries (15,16), with additional details being available at Lillytrials.com. From a post hoc pooled analysis, the advantage of duloxetine versus SSRl from these studies was estimated to be an effect size of 0.11 (16). For the sake of these retrospective comparisons, it can be assumed that this difference is the true advantage over SoC, or because the evidence for superiority of duloxetine was not definitive it can alternatively be assumed that the true difference is 0.
If each duloxetine arm is viewed as a PoC trial, the value of the active comparator in regard to benchmarking versus SoC can be compared to what would have been inferred based on a historical control. In other words, duloxetine can be compared head-to-head versus the SSRl and comparisons can be inferred by comparing the advantage of duloxetine over placebo to the historical advantage of SSRls, the SoC, over placebo.
It is important to realize that historical advantage in this context is different than the historical control as often described. Historical controls are often based on single-arm studies, comparing the response rate from a test drug to the response rate of a known effective drug (1, 17) . This is historical control based on uncontrolled studies. In the present context, historical comparisons versus SoC are based on placebo-controlled studies.
RESULTS
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Tables 1 and 2 summarize the outcome of comparisons versus SoC using the analytic distribution of the estimated treatment difference from scenarios 1 A and 1 B. In scenario 1 A, the experimental drug was superior to SoC therefore, if the criteria were used as the basis for continuing or discontinuing development, the rates in Table 1 are the probabilities of correctly continuing development of the test drug. Recall that N = 40 per arm yielded approximately 90% power for the test drug versus placebo if the test drug has the hoped-for effect. Therefore, 40 per arm would be adequate to compare the test drug with placebo. This sample size resulted in a probability of 81% for correctly ranking the treatments. With 100 per arm, the probability of establishing noninferiority was over 80%. With 200 per arm, the probability of establishing superiority was about 51.6%.
In scenario 1 B, the experimental drug was not different from SoC therefore, if the criteria were used as the basis for continuing or discontinuing development, the rates in Table 2 are the probabilities of wrongly continuing development of the drug believing it is superior to SOC.
Regardless of sample size, superiority testing yielded a false positive rate of 2.5%. It was still possible to establish noninferiority since the two treatments were in fact equal. arm, the probability of establishing noninferiority was over 51%. This demonstrates a difficulty in using noninferiority as the basis for continuing development when superiority is the goal. Namely, if the test drug is not really better than SoC, noninferiority tests when used as a less stringent assessment of potential for superiority can lead to many false conclusions that the test drug has potential to be superior. Moreover, the larger the sample size, the more likely this type of false positive result.
Using rankings also led to many false positive results. The probability of getting a point estimate of exactly zero difference between the experimental drug and SoC is negligible, and each drug will be ranked as better than the other about half the time. Of course, in a real situation, the true difference is not known and basing continued development on having the test drug be numerically superior to SoC would lead to a false positive rate of 50% regardless of sample size.
Interestingly, the probability of the estimated advantage of the experimental drug falling within the hoped-for range was 29.1% with N = 40, and with 200 per arm the rate was almost 16%. In other words, when there was no difference between drugs, there was still an appreciable probability that the estimated difference was consistent with the hoped-for difference, but this probability decreased with increasing sample size.
Tables 3 and 4 summarize the outcome of comparisons versus SoC using the analytic distribution of the estimated treatment difference from scenarios 2 A and 2B. respectively. In scenario 2A, the experimental drug was superior to SoC; therefore, if the criteria are used as the basis for continuing or discontinuing development, the rates in Table 3 are the probabilities of correctly continuing development of the test drug. In scenario 2B. the experimental drug was not different from SoC; therefore, if the criteria are used as the basis for continuing or discontinuing development, the rates in Table 4 are the probabilities of wrongly continuing development of the drug believing it is superior to SOC. Given that scenario 2 involved smaller effect sizes, the same sample size resulted in poorer operational characteristics as compared with scenario 1, with lower probabilities of correct positive results and higher probabilities of false positive results. Even with 500 per arm, there was only about 35% power for a superiority test. Again, increasing sample size when basing decisions on noninferiority increased the rate of erroneously concluding that the test drug could be superior to SoC. And basing decisions on rankings again yielded a 50% false positive rate if the experimental drug were no better than SOC.
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Interestingly, it took 500 per arm to yield a 72.3% probability that the point estimate fell within the hoped-for range when a difference existed. However, the point estimate fell within the hoped-for range in nearly 21.4% of the trials when no difference existed.
REAL DATA EXAMPLE OF USING A LITERATURE DATABASE TO BENCHMARK VERSUS SoC
Results from the duloxetine studies are summarized in Table 5 . First, consider the SSRl effect sizes and the duloxetine effect sizes from the studies that had an SSRl arm. The unweighted average SSRl effect size was 0.291, very close to the presumed true value of 0.31 reported in the large meta-analysis (6). However, the range in results was 0.09 to 0.637 and in only one of the seven studies was the observed SSRl effect size within fO.10 of the true value of 0.31 If assuming duloxetine is not different from SSRI, 4 of 11 concurrent control SSRl contrasts were within fO.10 of the true effect size of 0, whereas 6 of 11 historical contrasts fell within the same interval, and historical control was closer to the true value than concurrent control in 8 of 11 contrasts.
If assuming duloxetine is different from SSRl by the 0.11 estimated from the overall pooled data, 6 of 11 concurrent control SSRl contrasts were within fO.10 of the true effect size of 0.10. whereas 4 of 11 historical contrasts fell within the same interval. This comparison is biased in favor of the concurrent contrasts because of the assumption that the average concurrent contrast is the true difference. However, even with this bias, historical control was closer to the true value than concurrent control in 6 of 11 contrasts.
Duloxetine effect sizes were greater on average in the four studies without an active comparator. Papakostas and Fava (18) placebo led to greater drug-placebo differences. Based on historical control from the four studies that did not include an active comparator, the difference between duloxetine and SSRI would be an effect size of about 0.21. This result suggests two important points. First, when trading bias for precision in using historical controls, efforts to control bias, such as matching on key trial design features, can be beneficial. And sensitivity of results to various approaches should be evaluated. In addition, 12 of the 15 duloxetine treatment arms arose from having two identical studies run via the same protocol. Each arm was independently and adequately powered, but designed to be pooled to increase precision. Using the effect sizes for the duloxetine versus placebo contrast from the pooled data from each of the six study pairs and contrasting those six effect sizes versus historical control showed an effect size of -0.01 (40 mg HMAT, lowest dose), 0.108 (80 mg HMAT), 0.086 (80 mg HMAY), 0.232 (120 mg HMAY, highest dose), and 0.214 (60 mg HMBH. two-arm study).
In other words, three of the six pairs yielded an estimate extremely close to the final (overall) estimate; two of the less accurate estimates may have been influenced by dosing as these came from the highest and lowest dose; and one of the less accurate estimates came from a two-arm design, which yields larger effect sizes than studies with more treatment arms. Simply put, the efficacy of duloxetine versus SoC could have been inferred from historical control with approximately equal accuracy as from the concurrent control.
D I S C U S S I O N
There is an increasing need to understand the risks and benefits of a test drug compared with the SoC early in development. Even if a drug is superior to placebo it may not be worthwhile to
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continue development unless it has advantages over SoC. However, efficacy comparisons versus SoC in early phase studies can be challenging.
Analytic studies were conducted to illustrate the sample sizes needed for reliable comparisons of a test drug with SoC. Noninferiority testing and rankings yielded high rates of false positive results (continuing development when the test drug was not superior to SoC) at all sample sizes. Superiority testing yielded high rates of false negative results even when sample sizes were fivefold greater than what was needed to compare versus placebo.
However, only a few of the many scenarios and criteria for comparing a test drug with SoC were considered. Therefore, the main point of the examples above is not the specific results. Rather, the focus is on the general point that comparisons versus SoC take much larger studies than comparisons with placebo.
It is also important to consider that constructing valid comparisons versus SoC may require extensive experience with the test drug (4). In a PoC study, the dose of the test drug may not be the most appropriate dose to compare with SoC; or the most relevant patient population may not have been enrolled; or the most relevant outcomes on which to focus may not be known. Therefore, the value of comparing a test drug versus SoC in a PoC study is difficult to ascertain.
The example with clinical trial data in MDD illustrates how a literature database of placebocontrolled studies may be used to construct a historical comparison of a test drug with SoC. However, this retrospective illustration should be considered in the light of several factors. The potential for bias in non-head-to-head comparisons is well known and can be considerable (1.17). In situations such as clinical trials in MDD, where placebo response is highly variable, historical controls may be assumed to not be useful for definitive testing (18) (19) (20) (21) (22) .
Therefore, historical comparisons cannot be used as a substitute for adequate and well-controlled concurrent comparisons. However, historical comparisons may still be useful in the early evaluations of a test drug when adequate and well-controlled comparisons versus SoC may not be feasible.
While the depression example appears to be one wherein historical controls are useful, it involved a small number of studies and was retrospective. Evaluations across larger databases would be useful. Furthermore, major depressive disorder is a scenario where abundant historical data exists and individual clinical trial results are highly variable. Therefore this was an ideal area to consider historical data and may not be indicative of other scenarios.
Use of historical control as opposed to concurrent control is essentially a trade-off between bias and precision. If the bias in the historical control can be minimized and sufficient historical data exist so that the effects of SoC can be estimated precisely, as would often be the case for an SoC, then historical control can be useful.
It is interesting to consider these points in the context of researching a portfolio of drugs.
For example, given that test drugs often have no benefit, studies that focus on comparing a test drug with SoC may unnecessarily use resources that could be devoted to investigating other drugs. Consider the following hypothetical scenario where research and development costs are thought of as the opportunity to buy outcomes, with only a fixed amount that can be spent. Obviously, various strategies might be leveraged to buy outcomes more efficiently, but ultimately only so many outcomes can be bought. Further, assume that some outcomes are more expensive than others.
For example, in the present study sample sizes required to obtain a reliable contrast of the experimental drug versus SoC were at least fivefold greater than contrasts versus placebo. Given that certain costs associated with clinical trials are fixed regardless of sample size, assume contrasts versus SoC are threefold more costly than contrasts versus placebo. In other words, assume placebo outcomes cost 1 unit and SoC outcomes cost 3 units. Also assume that the research budget allows purchase of 20 outcome units.
If all PoC studies contain SoC, it would cost 4 pvIallh1ckrodt et al.
units to evaluate each compound (1 unit for the placebo outcome and 3 units for the SoC outcome). Hence, five compounds could be evaluated in total. If no PoC studies contained SoC, 12 compounds could be initially screened versus placebo, costing 12 units, for example. Then, assuming two compounds were positive, they would then be evaluated versus SoC. costing 8 units. In this hypothetical situation, would it be better to rigorously compare 5 compounds versus placebo and SoC, or would it be better to preliminarily evaluate 12 drugs versus placebo and only proceed to comparing versus SoC for those compounds that beat placebo, or is some combination of the approaches optimal?
Answering this question depends on many factors and a full discussion is beyond our present scope. However, the optimal solution is likely strongly influenced by the probability that the test drug is effective. For example, for test drugs with proven mechanisms of action, it is more likely that the compounds have some benefit and thus first testing versus placebo would not screen out many compounds. And there is likely greater need to compare versus SoC with the already proven compounds of the same mechanism as early as possible. Conversely, for test drugs with novel mechanisms, it is less likely that they will have any beneficial effect and a small trial versus placebo will screen out many compounds. Moreover, if the novel test drug happens to beat placebo, it is likely to differ in some meaningful way from the SoC. because it has a different mechanism. The key point is that comparisons versus SoC are costly and in a resource-constrained environment will result in the ability to evaluate fewer drugs.
Given that test drugs often have no benefit, studies that focus on comparing a test drug with SoC may unnecessarily use resources that could be devoted to investigating other drugs.
Given the importance of early evaluations of test drug versus SoC, other means of utilizing historical data should be considered. For example, Bayesian statistical approaches that explicitly incorporate prior data into the analysis may be useful (23.24). It may also be useful to consider adaptive designs. For an overview, see Chow and Chang (25) . For example, patients could be randomized to placebo, test drug, and SoC, with an interim analysis conducted when the test drug versus placebo contrast is adequately powered. If the interim result is positive, enrollment would continue until the test drug versus SoC contrast is sufficiently reliable. However, a discussion of Bayesian approaches and adaptive designs is beyond our present scope.
It is also beyond our present scope to discuss the myriad ways in which a test drug might be different from SoC. Nevertheless, if the sample sizes required for sufficiently reliable contrasts versus SoC on a primary efficacy outcome are not feasible, it is useful to consider all the potential ways a novel drug might differ from SoC in regard to safety outcomes, patient subgroups, and so on. As such, proof of concept for a novel drug could be demonstrated versus placebo, with comparisons versus SoC deferred until the larger phase 3 studies are conducted, assuming that the novel mechanism is likely to yield meaningful differences from SoC on some important outcomes.
C O N C L U S I O N
Many issues remain unresolved and more work is needed to understand how to optimize early comparisons of a test drug versus SoC. However, some points are clear. Powering a study versus placebo and then randomizing the same number of patients to SoC and contrasting SoC with the test drug can yield unreliable comparisons of test drug versus SoC. Therefore, it is important that the rate of false positive and false negative results be quantitatively evaluated before deciding upon the sample size and the criteria upon which the test drug and SoC will be compared. It may be useful to incorporate historical data in some manner to increase reliability of the test drug-SoC comparison.
